Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelimab plus chemotherapy and ivarmacitinib in first-line extensive-stage small cell lung cancer (Phase II)
ChiCTR2500104514Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivarmacitinib in small cell lung cancer (SCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: 6-month progression-free survival rate. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
ivarmacitinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500104514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104514.